Mirum Pharmaceuticals reports Q2 results after the bell today with short sellers retreating but options traders hedging into the print.
Short interest is elevated but moving in the right direction for longs. At 13.5% of the free float, the bearish overhang is real — yet that figure has dropped about 11% over the past month, with the most recent reading down another 3.4% in a single session on August 4. The lending market is loose rather than stressed: availability runs near 389%, meaning roughly four shares remain available to borrow for every one already on loan, and borrowing costs have fallen 20% over the past week to under 0.5%. There is no meaningful squeeze pressure here. The short score of 64.3 has actually drifted lower over the past two weeks, from a recent peak of 66.5 in late July, consistent with a gradual short-seller retreat rather than a conviction build.
Options positioning has turned more defensive into the print. The put/call ratio at 0.67 is well above its 20-day average of 0.51, running about 1.4 standard deviations elevated — a reading that reflects genuine demand for downside protection even if it falls well short of the 52-week high of 1.54. That shift in options sentiment coincides with a rough month for the stock, which has given back roughly 16% from its July highs to close at $105.79, despite a modest 1.4% bounce on Wednesday.
The analyst community is firmly in the bull camp, with all nine covering analysts carrying buy-equivalent ratings. RBC Capital lifted its target to $148 in early July, and JPMorgan raised to $125 at the start of that same month — both maintaining positive ratings while nudging numbers higher. The bull case centres on Livmarli's commercial momentum in Alagille syndrome, the planned NDA filing for volixibat in primary sclerosing cholangitis, and the strategic potential of the zilurgisertib acquisition. Bears flag the company's ongoing net losses, competitive risks across rare liver disease indications, and a price-to-book multiple that has compressed sharply — down 21 points over the past 30 days — reflecting just how much premium the stock had been carrying. One factor score worth noting: EPS surprise ranks in the 100th percentile, meaning Mirum has a near-perfect track record of beating estimates. The lone comparable earnings reaction in the data, from May 2026, saw the stock fall 2.7% on the day before recovering to post a 3.2% gain over the following week.
The institutional base adds texture. Frazier Life Sciences and Janus Henderson together hold roughly 24% of shares, both having added meaningfully in Q1. FMR (Fidelity) added over 1.3 million shares through June — a substantial build. Against that constructive institutional backdrop, the CEO and CFO both sold shares in early July at prices around $121–$125, about 15% above where the stock trades now. Those sales register at low significance scores and likely reflect routine exercise-and-sell activity, but the optics of executives selling well above the current price are worth noting heading into a print.
Tonight's report will test whether Livmarli's commercial trajectory and the volixibat NDA timeline can justify a re-rating back toward the $125–$148 range where most of the Street has clustered its targets — or whether the 16% pullback reflects a more durable reset in expectations.
See the live data behind this article on ORTEX.
Open MIRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
